A recent review article investigated the importance of hyaluronic acid chain lengths in eye drops for the physical as well as physiological performance of the drops. The classification according to average molecular weight was proposed: LMW HA (low molecular weight hyaluronic acid: < 1.5 MDa), MMW HA (medium molecular weight hyaluronic acid: 1.5 – 2.3 … Continue reading Hylan A supports the growth of corneal nerves in patients suffering from severe dry eye disease
Tag: hylan A
Why chain length of hyaluronan in eye drops matters
The chain length of hyaluronan (HA) determines its physical as well as its physiological properties. Results of clinical research on HA eye drops are not comparable without this parameter. In a recent article methods for the assessment of the average molecular weight of HA in eye drops and a terminology for molecular weight ranges are … Continue reading Why chain length of hyaluronan in eye drops matters
Meeting Bandi
On 24/25 October 1994 I attended in Brussels a meeting of the drug-device-borderline issues working group of the European Commission. One of the subjects on the agenda was whether to classify hyaluronan containing products for medical use as drugs or as medical devices under the new European Medical Devices Directive 93/42/EEC (MDD). Pharmacia was interested … Continue reading Meeting Bandi
Dr. Mueller-Lierheim 